Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy

Medical Hypotheses

Volumn 81, Issue 1, 2013, Pages 41-43

  Wang, Zhiyu ^a,b   Han, Jinxiang ^a,b   Cui, Yazhou ^b   Fan, Kaixi ^c   Zhou, Xiaoyan ^a,b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICRORNA 21; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; BCG VACCINATION; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL DIVISION; CELL MIGRATION; EFFECTOR CELL; HUMAN; PREDICTIVE VALUE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

BIOLOGICAL MARKERS; HUMANS; IMMUNOTHERAPY; MICRORNAS; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 84878535567     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.03.001     Document Type: Article

References (28)

1. Antonia S., Mulé J.J., Weber J.S. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004, 16:130-136.
2. Characiejus D., Hodzic J., Jacobs J.J. "First do no harm" and the importance of prediction in oncology. EPMA J 2010, 1:369-375.
3. Simon R. Moving from correlative science to predictive oncology. EPMA J 2010, 1:377-387.
4. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
5. Sharma P., Shen Y., Wen S., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007, 104:3967-3972.
6. Budhu S., Loike J.D., Pandolfi A., et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 2010, 207:223-235.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Provost P. Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. Aging (Albany, NY) 2010, 2:166-169.
9. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
10. Chen X., Ba Y., Ma L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
11. Monteagudo C., Martin J.M., Jorda E., Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 2007, 60:596-599.
12. Harlin H., Meng Y., Peterson A.C., et al. Chemokine expression in melanoma metastases associated with CD8+ T cell recruitment. Cancer Res 2009, 69:3077-3085.
13. Messina J.L., Yu H., Riker A.I., Munster P.N., Jove R.L., Daud A.I. Activated stat-3 in melanoma. Cancer Control 2008, 15:196-201.
14. Massi D., Tarantini F., Franchi A., et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 2006, 19:246-254.
15. Larue L., Delmas V. The WNT/Beta-catenin pathway in melanoma. Front Biosci 2006, 11:733-742.
16. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
17. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51.
18. Wang T., Niu G., Kortylewski M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
19. Burdelya L., Kujawski M., Niu G., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005, 174:3925-3931.
20. Olson P., Lu J., Zhang H., et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009, 23:2152-2165.
21. Ji J., Shi J., Budhu A., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
22. Kumarswamy R., Volkmann I., Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011, 8:706-713.
23. Gao W., Xu J., Liu L., Shen H., Zeng H., Shu Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother 2012, 66:21-28.
24. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010, 39:493-506.
25. Yang C.H., Yue J., Fan M., Pfeffer L.M. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010, 70:8108-8116.
26. Löffler D., Brocke-Heidrich K., Pfeifer G., et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110:1330-1333.
27. Wang H., Tan G., Dong L., et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012, 7:e34210.
28. Wu Z., Lu H., Sheng J., Li L. Inductive microRNA-21 impairs anti-mycobacterial responses by targeting IL-12 and Bcl-2. FEBS Lett 2012, 586:2459-2467.